Revelation Biosciences, Inc
Revelation Biosciences, Inc. is a U.S.-based clinical-stage life science company developing therapies built around its proprietary Gemini formulation of PHAD, an innate-immune modulator. Its pipeline includes programs for acute kidney injury, chronic kidney disease, post-surgical infection, and infection prevention in severe burn patients, with operations centered in San Diego, California.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueGemini-based drug candidates being developed for kidney disease and infection-related indications.
A worldwide licensed program using PHAD for treating or preventing infections.
Customers
Revelation does not yet sell approved products; its near-term counterparties are clinical investigators, contract research organizations, manufacturers, regulators, and licensing partners. If approved, its therapies would be used by physicians and hospitals treating acute kidney injury, chronic kidney disease, post-surgical infection, and severe burn patients.
Research sites, CROs, and vendors supporting preclinical and clinical development of Gemini programs.
Potential prescribers for AKI, CKD, post-surgical infection, and burn-related infection prevention.
Partners that could help fund, develop, or commercialize PHAD-based programs.
FDA and future payers that determine approval timing and market access.
Strategy
Revelation’s strategy is to advance Gemini through clinical development across multiple indications while preserving optionality through licensing and partnerships. It also seeks to broaden its pipeline through internal development, acquisitions, and in-licensing, while relying on third parties for manufacturing and future commercialization.
These are the core clinical programs and the main path to value creation.
Broadens the platform beyond kidney disease and increases pipeline optionality.
Clinical-stage biotech requires external capital and collaboration to progress.
Reduces capital intensity and leverages specialized third-party capabilities.
Geography
The company is incorporated in Delaware and based in San Diego, California, with development activities centered in the United States. Its business is currently U.S.-focused, although the Vanderbilt license is worldwide and any eventual commercialization could extend beyond the U.S.
Risks
Revelation faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory delays, and dependence on external capital. Its business is also exposed to single-supplier and third-party manufacturing reliance, plus the possibility that licensing terms, milestone obligations, or commercialization plans do not progress as expected.
- Clinical development failureImpact: CriticalLikelihood: High
Gemini programs must prove safety and efficacy in human trials before approval.
Exposure - Regulatory delay or rejectionImpact: HighLikelihood: High
FDA review and trial oversight determine whether programs can advance.
Exposure: All product candidates
- Capital dependence and dilutionImpact: HighLikelihood: High
The company funds operations through equity raises and may need more capital.
Exposure: Operating funding
- Manufacturing and supply concentrationImpact: HighLikelihood: Low
The company relies on third parties and has a single supplier for PHAD.
Exposure: PHAD and clinical supply chain
- Commercialization and reimbursement uncertaintyImpact: MediumLikelihood: Low
Even approved drugs need market access, pricing, and adoption by physicians/payers.
Exposure: Future approved products
Accounting
Judgemental itemsClinical and preclinical costs are expensed as incurred, making results highly dependent on trial activity.
Impact: Drives operating loss timing and comparability across periods
Outstanding warrants may be marked to market, creating non-cash volatility.
Impact: Can materially affect reported earnings and balance sheet values
The company depends on external funding to continue development.
Impact: Important for assessing liquidity and continuity of operations
Multiple reverse splits affect share counts and per-share metrics.
Impact: Impacts EPS, share price comparability, and market data
Similar listed companies
Publicly listed companies with a comparable business focus.
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
VivoSim Labs, INC.
VIVS · Biological Products, (No Diagnostic Substances)
Alumis Inc
ALMS · Pharmaceutical Preparations
ProKidney Corp
PROK · Biological Products, (No Diagnostic Substances)
Revvity, Inc
RVTY · Laboratory Analytical Instruments
Revvity is a U.S.-based health science company that develops instruments, software, reagents, and services used across research, screening, diagnostics, and reproductive health workflows.
Last updated: 24/09/2026